ADCETRIS (brentuximab vedotin) UK WEBSITE

ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):

  1. following autologous stem cell transplant (ASCT) or
  2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT.

ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

This website has been developed by Takeda Oncology and contains product and prescribing information intended for UK healthcare professionals. In addition, the site contains specific information for patients prescribed ADCETRIS. General information on sALCL and HL for the general public is also included.

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.

Reporting of side effects

ADCETRIS (brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. If you get any side effects whilst taking ADCETRIS, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed on this website or in the patient information leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of this medicine.